137 related articles for article (PubMed ID: 35318645)
1. Pregnane-based steroids are novel positive NMDA receptor modulators that may compensate for the effect of loss-of-function disease-associated GRIN mutations.
Kysilov B; Hrcka Krausova B; Vyklicky V; Smejkalova T; Korinek M; Horak M; Chodounska H; Kudova E; Cerny J; Vyklicky L
Br J Pharmacol; 2022 Aug; 179(15):3970-3990. PubMed ID: 35318645
[TBL] [Abstract][Full Text] [Related]
2. Surface Expression, Function, and Pharmacology of Disease-Associated Mutations in the Membrane Domain of the Human GluN2B Subunit.
Vyklicky V; Krausova B; Cerny J; Ladislav M; Smejkalova T; Kysilov B; Korinek M; Danacikova S; Horak M; Chodounska H; Kudova E; Vyklicky L
Front Mol Neurosci; 2018; 11():110. PubMed ID: 29681796
[TBL] [Abstract][Full Text] [Related]
3. Palmitoylation Controls NMDA Receptor Function and Steroid Sensitivity.
Hubalkova P; Ladislav M; Vyklicky V; Smejkalova T; Hrcka Krausova B; Kysilov B; Krusek J; Naimová Z; Korinek M; Chodounska H; Kudova E; Cerny J; Vyklicky L
J Neurosci; 2021 Mar; 41(10):2119-2134. PubMed ID: 33526476
[TBL] [Abstract][Full Text] [Related]
4. Site of Action of Brain Neurosteroid Pregnenolone Sulfate at the N-Methyl-D-Aspartate Receptor.
Hrcka Krausova B; Kysilov B; Cerny J; Vyklicky V; Smejkalova T; Ladislav M; Balik A; Korinek M; Chodounska H; Kudova E; Vyklicky L
J Neurosci; 2020 Jul; 40(31):5922-5936. PubMed ID: 32611707
[No Abstract] [Full Text] [Related]
5. Positive allosteric modulators that target NMDA receptors rectify loss-of-function GRIN variants associated with neurological and neuropsychiatric disorders.
Tang W; Liu D; Traynelis SF; Yuan H
Neuropharmacology; 2020 Oct; 177():108247. PubMed ID: 32712275
[TBL] [Abstract][Full Text] [Related]
6. Preferential Inhibition of Tonically over Phasically Activated NMDA Receptors by Pregnane Derivatives.
Vyklicky V; Smejkalova T; Krausova B; Balik A; Korinek M; Borovska J; Horak M; Chvojkova M; Kleteckova L; Vales K; Cerny J; Nekardova M; Chodounska H; Kudova E; Vyklicky L
J Neurosci; 2016 Feb; 36(7):2161-75. PubMed ID: 26888927
[TBL] [Abstract][Full Text] [Related]
7. Disease-associated nonsense and frame-shift variants resulting in the truncation of the GluN2A or GluN2B C-terminal domain decrease NMDAR surface expression and reduce potentiating effects of neurosteroids.
Kysilov B; Kuchtiak V; Hrcka Krausova B; Balik A; Korinek M; Fili K; Dobrovolski M; Abramova V; Chodounska H; Kudova E; Bozikova P; Cerny J; Smejkalova T; Vyklicky L
Cell Mol Life Sci; 2024 Jan; 81(1):36. PubMed ID: 38214768
[TBL] [Abstract][Full Text] [Related]
8. Novel neuroactive steroids as positive allosteric modulators of NMDA receptors: mechanism, site of action, and rescue pharmacology on GRIN variants associated with neurological conditions.
Tang W; Beckley JT; Zhang J; Song R; Xu Y; Kim S; Quirk MC; Robichaud AJ; Diaz ES; Myers SJ; Doherty JJ; Ackley MA; Traynelis SF; Yuan H
Cell Mol Life Sci; 2023 Jan; 80(2):42. PubMed ID: 36645496
[TBL] [Abstract][Full Text] [Related]
9. Pregn-5-en-3β-ol and androst-5-en-3β-ol dicarboxylic acid esters as potential therapeutics for NMDA hypofunction: In vitro safety assessment and plasma stability.
Matousova M; Soucek R; Tloustova E; Slavikova B; Chodounska H; Mertlikova-Kaiserova H; Kudova E
Steroids; 2019 Jul; 147():4-9. PubMed ID: 30296546
[TBL] [Abstract][Full Text] [Related]
10. Positive Allosteric Modulation as a Potential Therapeutic Strategy in Anti-NMDA Receptor Encephalitis.
Warikoo N; Brunwasser SJ; Benz A; Shu HJ; Paul SM; Lewis M; Doherty J; Quirk M; Piccio L; Zorumski CF; Day GS; Mennerick S
J Neurosci; 2018 Mar; 38(13):3218-3229. PubMed ID: 29476014
[No Abstract] [Full Text] [Related]
11. Access of inhibitory neurosteroids to the NMDA receptor.
Borovska J; Vyklicky V; Stastna E; Kapras V; Slavikova B; Horak M; Chodounska H; Vyklicky L
Br J Pharmacol; 2012 Jun; 166(3):1069-83. PubMed ID: 22188257
[TBL] [Abstract][Full Text] [Related]
12. The major brain cholesterol metabolite 24(S)-hydroxycholesterol is a potent allosteric modulator of N-methyl-D-aspartate receptors.
Paul SM; Doherty JJ; Robichaud AJ; Belfort GM; Chow BY; Hammond RS; Crawford DC; Linsenbardt AJ; Shu HJ; Izumi Y; Mennerick SJ; Zorumski CF
J Neurosci; 2013 Oct; 33(44):17290-300. PubMed ID: 24174662
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of NMDA receptor regulation.
Mony L; Paoletti P
Curr Opin Neurobiol; 2023 Dec; 83():102815. PubMed ID: 37988826
[TBL] [Abstract][Full Text] [Related]
14. De novo GRIN variants in NMDA receptor M2 channel pore-forming loop are associated with neurological diseases.
Li J; Zhang J; Tang W; Mizu RK; Kusumoto H; XiangWei W; Xu Y; Chen W; Amin JB; Hu C; Kannan V; Keller SR; Wilcox WR; Lemke JR; Myers SJ; Swanger SA; Wollmuth LP; Petrovski S; Traynelis SF; Yuan H
Hum Mutat; 2019 Dec; 40(12):2393-2413. PubMed ID: 31429998
[TBL] [Abstract][Full Text] [Related]
15. Geometry and charge determine pharmacological effects of steroids on N-methyl-D-aspartate receptor-induced Ca(2+) accumulation and cell death.
Weaver CE; Land MB; Purdy RH; Richards KG; Gibbs TT; Farb DH
J Pharmacol Exp Ther; 2000 Jun; 293(3):747-54. PubMed ID: 10869372
[TBL] [Abstract][Full Text] [Related]
16.
XiangWei W; Jiang Y; Yuan H
Curr Opin Physiol; 2018 Apr; 2():27-35. PubMed ID: 29756080
[TBL] [Abstract][Full Text] [Related]
17. Block of NMDA receptor channels by endogenous neurosteroids: implications for the agonist induced conformational states of the channel vestibule.
Vyklicky V; Krausova B; Cerny J; Balik A; Zapotocky M; Novotny M; Lichnerova K; Smejkalova T; Kaniakova M; Korinek M; Petrovic M; Kacer P; Horak M; Chodounska H; Vyklicky L
Sci Rep; 2015 Jun; 5():10935. PubMed ID: 26086919
[TBL] [Abstract][Full Text] [Related]
18. De novo GRIN variants in M3 helix associated with neurological disorders control channel gating of NMDA receptor.
Xu Y; Song R; Perszyk RE; Chen W; Kim S; Park KL; Allen JP; Nocilla KA; Zhang J; XiangWei W; Tankovic A; McDaniels ED; Sheikh R; Mizu RK; Karamchandani MM; Hu C; Kusumoto H; Pecha J; Cappuccio G; Gaitanis J; Sullivan J; Shashi V; Petrovski S; Jauss RT; Lee HK; Bozarth X; Lynch DR; Helbig I; Pierson TM; Boerkoel CF; Myers SJ; Lemke JR; Benke TA; Yuan H; Traynelis SF
Cell Mol Life Sci; 2024 Mar; 81(1):153. PubMed ID: 38538865
[TBL] [Abstract][Full Text] [Related]
19. A Rare Variant Identified Within the GluN2B C-Terminus in a Patient with Autism Affects NMDA Receptor Surface Expression and Spine Density.
Liu S; Zhou L; Yuan H; Vieira M; Sanz-Clemente A; Badger JD; Lu W; Traynelis SF; Roche KW
J Neurosci; 2017 Apr; 37(15):4093-4102. PubMed ID: 28283559
[TBL] [Abstract][Full Text] [Related]
20. Disease-Associated Variants in GRIN1, GRIN2A and GRIN2B genes: Insights into NMDA Receptor Structure, Function, and Pathophysiology.
Korinek M; Serra MC; Abdel Rahman F; Dobrovolski M; Kuchtiak V; Abramova V; Fili K; Tomovic E; Hrcka Krausova B; Krusek J; Cerny J; Vyklicky L; Balik A
Physiol Res; 2024 May; ():. PubMed ID: 38836461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
